Literature DB >> 26006328

Nanosponge-based pediatric-controlled release dry suspension of Gabapentin for reconstitution.

Monica R P Rao1, Rohini C Bhingole1.   

Abstract

CONTEXT: Gabapentin was selected to formulate oral controlled release dry suspension because of short biological half life of 5-7 h and low bioavailability (60%). Gabapentin is a bitter drug so an attempt was made to mask its taste.
OBJECTIVE: To formulate and evaluate controlled release dry suspension for reconstitution to increase the bioavailability and to control bitter taste of drug.
MATERIALS AND METHODS: Cyclodextrin based nanosponges were synthesized by previously reported melt method. The nanosponge-drug complexes were characterized by FTIR, DSC and PXRD as well as evaluated for taste and saturation solubility. The complexes were coated on Espheres by a suspension layering technique followed by coating with ethyl cellulose and Eudragit RS-100. A dry powder suspension for reconstitution of the microspheres was formulated and evaluated for taste, redispersibility, in vitro dissolution, sedimentation volume, leaching and pharmacokinetics. RESULTS AND DISCUSSION: The complexes showed partial entrapment of drug nanocavities. Significant decrease in solubility (25%) was observed in the complexes than pure drug in different media. The microspheres of nanosponge complexes showed desired controlled release profile for 12 h. Insignificant drug leaching was observed in reconstituted suspension during storage for 7 days at 45 °C/75% RH. Nanosponges effectively masked the taste of Gabapentin and the coating polymers provided controlled release of the drug and enhanced taste masking. The results of in vivo studies showed increase in bioavailability of controlled release suspension by 24.09% as compared to pure drug.
CONCLUSION: The dry powder suspension loaded with microspheres of nanosponges complexes can be proposed as a suitable controlled release drug delivery for Gabapentin.

Entities:  

Keywords:  Ethyl cellulose; Eudragit RS-100; Gabapentin; nanosponges; pan coating; taste masking

Mesh:

Substances:

Year:  2015        PMID: 26006328     DOI: 10.3109/03639045.2015.1044903

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  7 in total

1.  Atazanavir-Loaded Crosslinked Gamma-Cyclodextrin Nanoparticles to Improve Solubility and Dissolution Characteristics.

Authors:  Darshana Dhabliya; Shagufta Abdul Qaiyum Khan; Minal Umate; Bhavana Raut; Dilesh Singhavi
Journal:  Turk J Pharm Sci       Date:  2022-08-31

2.  20(S)-Protopanaxadiol Phospholipid Complex: Process Optimization, Characterization, In Vitro Dissolution and Molecular Docking Studies.

Authors:  Yiqiong Pu; Xitong Zhang; Qi Zhang; Bing Wang; Yuxi Chen; Chuanqi Zang; Yuqin Wang; Tina Ting-Xia Dong; Tong Zhang
Journal:  Molecules       Date:  2016-10-19       Impact factor: 4.411

Review 3.  History of Cyclodextrin Nanosponges.

Authors:  Ilona Krabicová; Silvia Lucia Appleton; Maria Tannous; Gjylije Hoti; Fabrizio Caldera; Alberto Rubin Pedrazzo; Claudio Cecone; Roberta Cavalli; Francesco Trotta
Journal:  Polymers (Basel)       Date:  2020-05-14       Impact factor: 4.329

4.  Evaluation and Characterization of Curcumin-β-Cyclodextrin and Cyclodextrin-Based Nanosponge Inclusion Complexation.

Authors:  Hadeia Mashaqbeh; Rana Obaidat; Nizar Al-Shar'i
Journal:  Polymers (Basel)       Date:  2021-11-24       Impact factor: 4.329

Review 5.  The ascension of nanosponges as a drug delivery carrier: preparation, characterization, and applications.

Authors:  Kartik Tiwari; Sankha Bhattacharya
Journal:  J Mater Sci Mater Med       Date:  2022-03-04       Impact factor: 3.896

Review 6.  Ethylcellulose-A Pharmaceutical Excipient with Multidirectional Application in Drug Dosage Forms Development.

Authors:  Katarzyna Wasilewska; Katarzyna Winnicka
Journal:  Materials (Basel)       Date:  2019-10-17       Impact factor: 3.623

7.  Formulation and evaluation of cyclodextrin-based nanosponges of griseofulvin as pediatric oral liquid dosage form for enhancing bioavailability and masking bitter taste.

Authors:  Samia M Omar; Fares Ibrahim; Aliaa Ismail
Journal:  Saudi Pharm J       Date:  2020-02-03       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.